Tags

Type your tag names separated by a space and hit enter

Metformin versus flutamide in the treatment of metabolic consequences of non-obese young women with polycystic ovary syndrome: a randomized prospective study.
Gynecol Endocrinol 2004; 19(3):115-24GE

Abstract

In addition to the reproductive consequences, polycystic ovary syndrome (PCOS) is characterized by a metabolic disorder in which hyperinsulinemia and insulin resistance are central features. The effects and possible benefits from insulin-sensitizing drugs are not well known, especially in non-obese women with PCOS. This study was designed to evaluate the effects of metformin and flutamide on metabolic parameters and insulin resistance in non-obese women with PCOS. Thirty non-obese women newly diagnosed with PCOS and 15 age- and weight-matched healthy volunteers as controls were included in the study. Patients were assigned randomly to receive flutamide 250 mg daily or metformin 850 mg three times daily. Glucose, insulin, insulin resistance, androgen levels and glucose and insulin responses to an oral glucose tolerance tests (OGTT) were assessed before and after a 4-week therapy period. A positive correlation was found between body mass index and insulin level in patients with PCOS and controls. Follicle stimulating hormone, luteinizing hormone, free testosterone and dehydroepiandrosterone sulfate levels decreased significantly, but insulin resistance levels were not changed after flutamide therapy. Body weight, free testosterone, insulin and insulin resistance levels decreased significantly after metformin therapy. In conclusion, metformin treatment improved insulin sensitivity and decreased androgen levels, and flutamide decreased androgen levels but failed to improve insulin sensitivity in the non-obese women with PCOS.

Authors+Show Affiliations

Department of Endocrinology and Metabolic Diseases, Faculty of Medicine, Inonu University, Malatya, Turkey.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

15697072

Citation

Sahin, I, et al. "Metformin Versus Flutamide in the Treatment of Metabolic Consequences of Non-obese Young Women With Polycystic Ovary Syndrome: a Randomized Prospective Study." Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology, vol. 19, no. 3, 2004, pp. 115-24.
Sahin I, Serter R, Karakurt F, et al. Metformin versus flutamide in the treatment of metabolic consequences of non-obese young women with polycystic ovary syndrome: a randomized prospective study. Gynecol Endocrinol. 2004;19(3):115-24.
Sahin, I., Serter, R., Karakurt, F., Demirbas, B., Culha, C., Taskapan, C., ... Aral, Y. (2004). Metformin versus flutamide in the treatment of metabolic consequences of non-obese young women with polycystic ovary syndrome: a randomized prospective study. Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology, 19(3), pp. 115-24.
Sahin I, et al. Metformin Versus Flutamide in the Treatment of Metabolic Consequences of Non-obese Young Women With Polycystic Ovary Syndrome: a Randomized Prospective Study. Gynecol Endocrinol. 2004;19(3):115-24. PubMed PMID: 15697072.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Metformin versus flutamide in the treatment of metabolic consequences of non-obese young women with polycystic ovary syndrome: a randomized prospective study. AU - Sahin,I, AU - Serter,R, AU - Karakurt,F, AU - Demirbas,B, AU - Culha,C, AU - Taskapan,C, AU - Kosar,F, AU - Aral,Y, PY - 2005/2/9/pubmed PY - 2005/3/4/medline PY - 2005/2/9/entrez SP - 115 EP - 24 JF - Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology JO - Gynecol. Endocrinol. VL - 19 IS - 3 N2 - In addition to the reproductive consequences, polycystic ovary syndrome (PCOS) is characterized by a metabolic disorder in which hyperinsulinemia and insulin resistance are central features. The effects and possible benefits from insulin-sensitizing drugs are not well known, especially in non-obese women with PCOS. This study was designed to evaluate the effects of metformin and flutamide on metabolic parameters and insulin resistance in non-obese women with PCOS. Thirty non-obese women newly diagnosed with PCOS and 15 age- and weight-matched healthy volunteers as controls were included in the study. Patients were assigned randomly to receive flutamide 250 mg daily or metformin 850 mg three times daily. Glucose, insulin, insulin resistance, androgen levels and glucose and insulin responses to an oral glucose tolerance tests (OGTT) were assessed before and after a 4-week therapy period. A positive correlation was found between body mass index and insulin level in patients with PCOS and controls. Follicle stimulating hormone, luteinizing hormone, free testosterone and dehydroepiandrosterone sulfate levels decreased significantly, but insulin resistance levels were not changed after flutamide therapy. Body weight, free testosterone, insulin and insulin resistance levels decreased significantly after metformin therapy. In conclusion, metformin treatment improved insulin sensitivity and decreased androgen levels, and flutamide decreased androgen levels but failed to improve insulin sensitivity in the non-obese women with PCOS. SN - 0951-3590 UR - https://www.unboundmedicine.com/medline/citation/15697072/Metformin_versus_flutamide_in_the_treatment_of_metabolic_consequences_of_non_obese_young_women_with_polycystic_ovary_syndrome:_a_randomized_prospective_study_ L2 - http://www.diseaseinfosearch.org/result/7590 DB - PRIME DP - Unbound Medicine ER -